New drug duo shows promise against tough cancers
NCT ID NCT05027139
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tested whether two drugs, zanidatamab and evorpacept, are safe and can shrink tumors in people with advanced HER2-expressing cancers. Fifty-two patients with breast or other cancers that had spread or couldn't be removed by surgery took part. The goal was to see how many patients responded and to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanidatamab and evorpacept (drugs given intravenously)
What this could lead to
If this combination works, it could offer a new treatment option for people with advanced HER2-expressing cancers that are hard to treat.
What could go wrong
This is an early-phase trial with only 52 participants, so results may not apply to everyone. Side effects are possible, and the combination may not shrink tumors in all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Astera Cancer Care
East Brunswick, New Jersey, 08816, United States
-
Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Magee-Womens Hospital of UPMC
Pittsburgh, Pennsylvania, 15213, United States
-
Northwest Medical Specialties, PLLC
Tacoma, Washington, 98405, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UC Irvine Health - Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UC San Diego - Moores Cancer Center
La Jolla, California, 92093, United States
-
UCLA Department of Medicine Hematology/Oncology
Los Angeles, California, 90095, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Vermont Medical Center
Burlington, Vermont, 05401, United States
-
University of Wisconsin - Madison
Madison, Wisconsin, 53792, United States